Johnson & Johnson : New Results from the Phase 3 GLOW Study

NEW ORLEANS, December 10, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study , which... | December 10, 2022

Related Keywords

Denmark , United States , Copenhagen , Køavn , American , Craig Tendler , Obinutuzumab Clb , Carsten Niemann , Christie Corbett , None Of The Janssen Pharmaceutical Companies , Global Medical Affairs , Slate Development , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Drug Administration , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , American Society Of Hematology , Companies Of Johnson , International Workshop , Johnson , American Cancer Society , Clinical Associate Professor , Principal Investigator , Hazard Ratio , Vice President , Janssen Research , Janssen Biotech , Cardiac Failure , Sudden Death , Primary Malignancies , Lysis Syndrome , Fetal Toxicity , B Cell Malignancies , Hepatic Impairment , Prescribing Information , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Disease Kinetics Among Patients , High Risk Factors Treated , First Line Fixed Duration Ibrutinib , Hematology Annual , Chronic Lymphocytic , Accessed December , Outcomes After Undetectable , First Line Ibrutinib , Plus Venetoclax , Fixed Duration Treatment , Median Follow Up , First Line Treatment , Participants With Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Johnson Stock Exchange , News , Information , Press Release , Few , December , 022 , The , Janssen , Harmaceutical , Companies , F , Oday , Nnounced , Results , Rom , Hase , , Low , Tudy Jnj Us4781601046 ,